Over 10 Million Merchants Join Five Fortune Card Campaign on Alipay Platform to Further Engage With Consumers Ahead of CNY
Over 10 million brands and merchants in China joined Alipay’s signature annual Five Fortune Card Collection campaign for the 2023 Chinese New Year, ramping up digital efforts to attract and engage mobile-savvy consumers, as Chinese consumers gear up for the most important festival of the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230121005044/en/
A user trying to collect a fortune card by scanning the Chinese character “fu” with AR scan feature in Alipay app (Photo: Business Wire)
This year’s campaign, from January 10, 2023 to January 21, attracted more than 30,000 blue chip and emerging international and domestic brands and over 10 million small and micro business participants seeking to enhance their interaction with Chinese consumers in anticipation of the Spring Festival. This represented a nearly 30 times increase in the number of brands that participated in the campaign last year.
“As an open platform, Alipay is committed to opening up products and technologies to facilitate merchants’ digital transformation. We have also introduced Five Fortune Card IP-related resources to our partners,” said Yongming He, General Manager of the Alipay Ecosystem Development Business Unit and Vice President of Ant Group. “We are glad to see a growing number of brands and merchants participating in the Alipay Five Fortune Card Collection campaign to enhance engagement with users and improve operational efficiency by leveraging digital tools, including mini program and livestreaming, on the Alipay platform.”
Initially launched in 2015, Alipay's Five Fortune Card Collection campaign is an annual event before the Chinese New Year. Users collect digital fortune cards by using the Alipay app's AR scan feature and participating in merchant campaigns, among various ways to win a fortune card. These cards represent good wishes and can be converted into monetary rewards.
This year, for the first time, users can receive a limited-edition digital collectible featuring Chinese intangible cultural heritage, including shadow puppetry, paper-cut and copper sculpture, after successfully obtaining five fortune cards in the campaign.
Users can win a fortune card when they scan the red envelope QR code each time at the outlets of the 10 million participating merchants. They may also obtain cards by logging into Alipay mini programs or by watching livestreams of more than 30,000 participating brands on Alipay. Through these livestreams, brands distributed fortune cards to participants, introduced their products and services, and gave out preferential benefits to build connections with mobile-savvy Chinese consumers.
Merchants and brands have seen significant digital engagement through their participation in the Alipay campaign, with millions of views from livestreaming. On January 11, No. 1 Job Club, a job search service provider, saw 20 million visits to their livestreaming on Alipay platform. On the same day, Yunchongbao, a pet service provider, witnessed 50 million visits to their Alipay livestream. And on January 15, the NBA attracted over 12 million visits to their Alipay livestream which was moderated by several local basketball influencers. These numbers demonstrate the success of the campaign in attracting digital participation from merchants and brands, as reflected in the large livestream audience engagement on the Alipay platform.
Pop-Mart, a culture and entertainment company that is best known for art and collectible toys who introduced the idea of "blind box”, attracted three million visits to their Alipay mini-program six days into the campaign, with its transaction volume through the Alipay platform increasing 300% compared with that of last month.
About Alipay
In the evolving digital era, Alipay has transformed from a trusted payment tool to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operations on the Alipay platform, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than one billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230121005044/en/
Contact information
Media Enquiry
Bell Wang
yixing.wl@antgroup.com
+86 138 1038 5201
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom